Bibliographie générale

Translating IL-6 biology into effective treatments.

Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T.

Nat Rev Rheumatol. 2020 Apr 23

Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.

Pai RL, Japp AS, Gonzalez M, Rasheed RF, Okumura M, Arenas D, Pierson SK, Powers V, Layman AAK, Kao C, Hakonarson H, van Rhee F, Betts MR, Kambayashi T, Fajgenbaum DC.

JCI Insight. 2020 May 7;5(9)

Increased mTOR activation in idiopathic multicentric Castleman disease.

Arenas DJ, Floess K, Kobrin D, Pai RL, Srkalovic MB, Tamakloe MA, Rasheed R, Ziglar J, Khor J, Parente SAT, Pierson SK, Martinez D, Wertheim GB, Kambayashi T, Baur J, Teachey DT, Fajgenbaum DC.

Blood. 2020 Mar 23.  [Epub ahead of print]

Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease

Fajgenbaum DC, Langan RA, Japp AS, Partridge HL, Pierson SK, Singh A, Arenas DJ, Ruth JR, Nabel CS, Stone K, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Jordan MB, Cohen AD, Krymskaya V, Rubenstein A, Betts MR, Kambayashi T, van Rhee F, Uldrick TS. J Clin Invest. 2019;130:4451-4463

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.

abel CS, Sameroff S, Shilling D, Alapat D, Ruth JR, Kawano M, Sato Y, Stone K, Spetalen S, Valdivieso F, Feldman MD, Chadburn A, Fosså A, van Rhee F, Lipkin WI, Fajgenbaum DC. PLoS One. 2019 Jun 26;14(6):e0218660.

Treatment and outcome of Unicentric Castleman Disease: a retrospective analysis of 71 cases.

Boutboul D, Fadlallah J, Chawki S, Fieschi C, Malphettes M, Dossier A, Gérard L, Mordant P, Meignin V, Oksenhendler E, Galicier L. Br J Haematol. 2019;186(2):269-273.

A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease.

Baker TS, Gambino KJ, Schriefer L, Lim JY, Steinberg KM, Fajgenbaum DC, Martín García-Sancho A, Byun M. Blood Adv. 2018;2(21):2959-2963.

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.

Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC. Br J Haematol. 2018 Sep 11.

ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease.

Van Nieuwenhove E, Humblet-Baron S, Van Eyck L, De Somer L, Dooley J, Tousseyn T, Hershfield M, Liston A, Wouters C. Pediatrics. 2018 Sep;142(3). 2017-2266.

Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.

Nagy A, Bhaduri A, Shahmarvand N, Shahryari J, Zehnder JL, Warnke RA, Mughal T, Ali S, Ohgami RS. Blood Adv. 2018 Mar 13;2(5):481-491.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

Van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. Blood. 2018 Nov 15;132(20):2115-2124. Epub 2018 Sep 4. Review.

The full spectrum of Castleman disease: 273 patients studied over 20 years.

Oksenhendler E, Boutboul D, Fajgenbaum D, Mirouse A, Fieschi C, Malphettes M, Vercellino L, Meignin V, Gérard L, Galicier L. Br J Haematol. 2018 Jan;180(2):206-216

Clinical and molecular characteristics of unicentric mediastinal Castleman disease.

Legras A, Tallet A, Didelot A, Cazes A, Danel C, Hin A, Borie R, Crestani B, Castier Y, Bagan P, Le Pimpec-Barthes F, Riquet M, Blons H, Mordant P. J Thorac Dis. 2018 Apr;10(4):2079-2088.

Multicentric Castleman disease: Where are we now?

Wang HW, Pittaluga S, Jaffe ES. Semin Diagn Pathol. 2016 May 16

Idiopathic multicentric Castleman's disease: a systematic literature review.

Liu AY, Nabel CS, Finkelman BS, et al. Lancet Haematol. 2016 Apr;3(4):e163-75.

Use of a claims database to characterize and estimate the incidence rate for Castleman disease.

Munshi N1, Mehra M, van de Velde H, Desai A, Potluri R, Vermeulen J. Leuk Lymphoma. 2015 May;56(5):1252-60.

The use of monoclonal antibodies to treat Castleman's disease.

Robey RC, Mletzko S, Colley C, Balachandran K, Bower M. Immunotherapy. 2014;6(2):211-9.

Surgery in Castleman's disease: a systematic review of 404 published cases.

Talat N, Belgaumkar AP, Schulte KM. Ann Surg. 2012 Apr;255(4):677-84

Castleman's disease: systematic analysis of 416 patients from the literature.

Talat N, Schulte KM. Oncologist. 2011;16(9):1316-24.

The spectrum of Castleman's disease: mimics, radiologic pathologic correlation and role of imaging in patient management.

Madan R, Chen JH, Trotman-Dickenson B, Jacobson F, Hunsaker A. Eur J Radiol. 2012 Jan;81(1):123-31.

Castleman disease.

Dispenzieri A. Cancer Treat Res. 2008;142:293-330.

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

Nishimoto N, Kanakura Y, Aozasa K, et al. Blood. 2005 Oct 15;106(8):2627-32.

Paediatric Castleman disease: report of seven cases and review of the literature.

Parez N, Bader-Meunier B, Roy CC, Dommergues JP. Eur J Pediatr. 1999 Aug;158(8):631-7.

Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type.

Ohyashiki JH, Ohyashiki K, Kawakubo K, et al. Am J Clin Pathol. 1994 Mar;101(3):290-5

Multicentric Castleman's disease.

Peterson BA, Frizzera G. Semin Oncol. 1993 Dec;20(6):636-47

Angiofollicular lymphoid hyperplasia (Castleman's disease) in two mice treated with polyoma virus or urethane.

Williams AO, Banks PM, Liebelt AG, Stewart HL, Saffiotti U. Toxicol Pathol. 1993;21(1):26-34.

Localized mediastinal lymph node hyperplasia resembling thymoma.

Castleman B, Iverson L, Menendez VP. Cancer. 1956 Jul-Aug;9(4):822-30.

CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises: Case 40011.

N Engl J Med. 1954 Jan 7;250(1):26-30